Preparation and characterization of novel pseudo ceramide-based nanostructured lipid carriers for transdermal delivery of apigenin
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Drug Delivery Science and Technology"
DOI: 10.1016/j.jddst.2018.09.019
Abstract: Abstract In this study, pseudo ceramide-based nanostructured lipid carriers (NLCs) were prepared for the transdermal delivery of apigenin (APG). The characterization of APG-NLC9, 6, and 3 containing pseudo ceramide with 1, 2, and 3 double… read more here.
Keywords: pseudo ceramide; delivery; based nanostructured; nanostructured lipid ... See more keywords
Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Demonstrates Robust Antitumor Activity in Preclinical Models of T-Cell Lymphomas (TCLs)
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-202655
Abstract: Introduction TCLs encompass a heterogeneous group of hematologic neoplasms derived from clonal proliferation of T lymphocytes and are often characterized by aggressive clinical behavior and poor prognosis. Enhancer of zeste homolog 2 (EZH2), as a… read more here.
Keywords: apg 5918; apg; cell; tcls ... See more keywords
A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.3125
Abstract: 3125 Background: APG-1387 is a novel, bivalent small molecule IAP (inhibitor of apoptosis proteins) inhibitor. It has shown strong antitumor activities in multiple human xenograft cancer models. APG-1387 also acts as host immune modulator, supporting… read more here.
Keywords: combination pembrolizumab; apg; apg 1387; study ... See more keywords